covid
Buscar en
Inmunología
Toda la web
Inicio Inmunología HLA class I association with progression to end-stage renal disease in patients ...
Información de la revista
Vol. 31. Núm. 2.
Páginas 37-42 (abril - junio 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
7523
Vol. 31. Núm. 2.
Páginas 37-42 (abril - junio 2012)
Original article
Acceso a texto completo
HLA class I association with progression to end-stage renal disease in patients from Zulia, Venezuela
Asociación de antígenos HLA clase I con la progresión a enfermedad renal terminal en pacientes zulianos de Venezuela
Visitas
7523
Sergio Rivera P.a,b,
Autor para correspondencia
sergio.rivera54@hotmail.es

Corresponding author.
, Georgina Márquezb, Ana Maria Cipriania, Manzur Hassanhia, Carmen C. Villalobosb, Alba Fuenmayorb, Maribel Chaveza, Milagros Montiela
a Department of Transmissible Diseases, University of Zulia (LUZ), Venezuela
b HLA and Immunology Laboratory, Blood Bank of Zulia State, Venezuela
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (4)
Table 1. HLA-A class I antigen frequencies in patients with ESRD and control group of Zulian population.
Table 2. HLA-B class I antigen frequencies in patients with ESRD and control group of Zulian population.
Table 3. HLA-A9 and HLA-B12 negative association with ESRD remained after Bonferroni correction applied.
Table 4. Association of HLA-A-B two loci haplotypes class I in patients with ESRD and control group of the Mestizos Zulian population.
Mostrar másMostrar menos
Abstract

The aim of this study was to determine HLA associations with progression to end-stage renal disease (ESRD) in the mixed Zulian population in Venezuela, regardless of other factors. A retrospective study to determine HLA Class I association was performed on 188 patients with ESRD due to different types of glomerulonephritis, and 202 healthy controls. Patients and control groups were serologically typed by Terasaki microlymphocytotoxicity technique using commercial Class I plates including 26 HLA-A and 48 HLA-B specificities. The antigens positively associated to the ESRD were: HLA-B38, B51, B53 and B62. Negatively associated antigens were: HLA-A9, B12, B17, B40 and B48. The haplotypes positively associated were: HLA-A2-B51, A2-B53, A23-B38 and A68-B38. The negatively associated haplotypes were: HLA-A2-B12, A2-B48, A9-B35 and A28-B40. The high Odds ratio observed and its statistical corroboration reflect the strength of the described association between HLA antigens and ESRD. Further molecular studies should clarify types and subtypes of the HLA class I alleles involved in the progression to ESRD.

Keywords:
End-stage renal disease
HLA-class I antigens
Association
Resumen

El objetivo principal de este trabajo fue determinar las posibles asociaciones de los antígenos HLA con la progresión a enfermedad renal terminal (ESRD por las siglas en inglés), independientemente de otros factores, en la población Zuliana de Venezuela. Se trata de un estudio retrospectivo, analizando los resultados obtenidos de la tipificación de los antígenos HLA clase I (A y B) en 188 pacientes con enfermedad renal crónica en etapa terminal y con indicación de trasplante renal, en comparación con 202 controles sanos de la misma población. Los antígenos HLA fueron tipificados por la técnica de microlinfocitotoxicidad de Terasaki, utilizando placas comerciales para clase I incluyendo 26 especificidades HLA-A y 48 HLA-B. Los antígenos HLA clase I asociados a ESRD fueron: HLA-B38, B51, B53, B62; y los asociados negativamente resultaron HLA-A9, B12, B17, B40, B48. Los haplotipos asociados positivamente fueron: HLA-A2-B51, A2-B53, A23-B38 y A68-B38. Los haplotipos asociados negativamente resultaron: HLA-A2-B12, A2-B48, A9-B35, A28-B40. Los altos riesgos relativos observados y su corroboración estadística reflejan la fortaleza de las asociaciones descritas. Estos resultados podrían orientar los estudios moleculares que permitirán determinar y confirmar de manera más específica cuáles son los alelos HLA clase I asociados con esta patología.

Palabras clave:
Enfermedad renal terminal
HLA clase I
Asociación
Texto completo
Introduction

Progression of chronic renal failure (CRF) leads, in the majority of instances to end-stage renal disease (ESRD) at which point renal replacement therapy is irremediable. Since the mid-1980s, there has been a marked increase in the incidence and prevalence of ESRD around the world.1

Gender, genetic, race, lipids, hypertension, and smoking are the associated factors among others to the ESRD.2 The role of the immune system in renal diseases must also be considered, because it could be the origin or cause of the disease and its progression.3 These observations resulted in the search for positive associations between human leukocyte antigens (HLA) and a wide range of renal diseases. Nevertheless, it is only in glomerulonephritis where a convincing rationale for such studies has been demonstrated. The studies on HLA and renal diseases show some striking associations with HLA Class I and Class II alleles. The approach to the analysis of HLA associations with renal disease has evolved since the late 1980s, mainly because of the much deeper understanding of Class I and Class II molecules structure and function. HLA phenotypes are correlated with an increased or decreased risk of alloantibody sensitization (PRA) in end-stage renal disease candidates for first or repeat kidney transplantation.4 This study provides evidence that HLA-linked genes influence the anti-HLA alloantibody sensitization in ESRD. Various pathologies may be associated to HLA alleles and/or haplotypes such as idiopathic membranous nephropathy, minimal change nephrotic syndrome, immunoglobulin A (IgA) nephropathy, post-streptococcal glomerulonephritis and familial focal glomerulosclerosis, among others.5-12 Family studies of the HLA Class II system in acute post-streptococcal glomerulonephritis in the population of Zulia State confirm the association between HLA alleles and the disease.13

The purpose of this study was to determine if specific HLA Class I antigens or combinations of antigens are associated with progression to ESRD, regardless of other factors, in patients of the population of Zulia state, Venezuela.

Materials and methods

A retrospective study was conducted using results of serological microlymphocitotoxicity Terasaki test, obtained from samples submitted to the HLA and Immunology Laboratory of the Zulia State Blood Bank, between 1985 and 2003. A total of 188 patients with ESRD, in their majority reported as post-streptococcal or other glomerulonephritis origin and 202 healthy controls of Zulian population were evaluated. For this study, ESRD was defined as a moment when long-term treatment with dialysis was initiated and a transplant was required for survival. The patients were referred from the Nephrology Service of the University Hospital of Zulia State. The control group includes both sex non-related subjects with ages between 20 and 72 years old. The results obtained with serological commercial test from HLA Class I (BIOTEST Diagnostics, One Lambda or C six Diagnostics, INC) following the manufacturers recommendations were analyzed; they included 26 HLA-A and 48 HLA-B specificities. Antigenic frequencies were determined for each subject's HLA14 and haplotypes frequencies were calculated by the Mattiuz method.15 The results were analyzed by the Chi square statistical method, corrected by Yates [pc=1(1p)n], Fisher's exact; p-value (1-tail) or Bonferroni test when necessary; p<0.05 was considered statistically significant.16 Odds ratio (O.R.) was used to estimate the association's strength between HLA antigens and ESRD.17,18 Preventive Fraction (PF) indicates how much protection was assigned to the marker.16

Results

The age range of the 188 patients was between 20 and 44 years, with a median age of 34.3 years. A total of 117 (62.5%) patients were males and 71 (38.5%) females. In the controls, 107 (52.97%) were females and 95 (47.03%) were males.

HLA-B38, B51, B53 and B62 antigens were positively associated to the ESRD. The HLA-A9, B12, B17, B40 and B48 antigens showed a negative association to the ESRD (Tables 1 and 2). Only HLA-A9 and HLA-B12 negative association with ESRD remained after Bonferroni correction applied (Table 3).

Table 1.

HLA-A class I antigen frequencies in patients with ESRD and control group of Zulian population.

Frequencies
ControlsN=203ESRD patientsN=188
HLA antigens  n  F  fg  n  F  fg  P  O.R.  PF 
A1  33  0.0813  0.0415  27  0.0718  0.0366  NS  0.9   
A2  116  0.3005  0.1636  101  0.2793  0.1510  NS  0.87   
A3  25  0.0665  0.0338  31  0.0824  0.0421  NS  1.41   
A9  24  0.0517  0.0262  0.0160  0.0080  0.0019  0.25  0.38 
A10  0.0222  0.0111  10  0.0266  0.0134  NS  1.21   
A11  27  0.0714  0.0364  19  0.0505  0.0256  NS  0.73   
A19  10  0.0271  0.0136  0.0239  0.0120  NS  0.97   
A23  10  0.0246  0.0124  19  0.0505  0.0256  NS  2.17   
A24  44  0.1108  0.0570  42  0.1170  0.0575  NS  1.04   
A25  0.0074  0.0037  0.0027  0.0013  NS  0.36   
A26  11  0.0271  0.0136  0.0160  0.0080  NS  0.58   
A28  25  0.0616  0.0313  18  0.0479  0.0242  NS  0.75   
A29  12  0.0296  0.0149  20  0.0585  0.0297  NS  1.89   
A30  16  0.0419  0.0212  19  0.0505  0.0256  NS  1.31   
A31  0.0172  0.0087  15  0.0399  0.0201  NS  2.43   
A32  0.0222  0.0111  0.0106  0.0053  NS  0.47   
A33  12  0.0296  0.0149  16  0.0426  0.0215  NS  1.48   
A34  0.0025  0.0012  0.0000  0.0000  NS  0.36   
A36  0.0049  0.0025  0.0027  0.0013  NS  0.54   
A43  0.0025  0.0012  0.0000  0.0000  NS  0.36   
A66  0.0025  0.0012  0.0053  0.0027  NS  2.17   
A68  0.0074  0.0037  0.0160  0.0080  NS  2.20   
A2403  0.0025  0.0012  0.0053  0.0027  NS  2.17   
A74  0.0049  0.0025  0.0000  0.0000  NS  0.21   
A80  0.0049  0.0025  0.0000  0.0000  NS  0.21   
Black  0.0000  0.0000  0.0053  0.0027  NS  5.46   

n: number of antigens, F: antigen frequencies, gf: gene frequencies, P: probability, NS: no significant, O.R.: Odds ratio, N: number of individuals, ESRD: end stage renal disease, PF: preventive fraction.

Table 2.

HLA-B class I antigen frequencies in patients with ESRD and control group of Zulian population.

ControlsN=203ESRD patientsN=188
HLA antigens  n  f  gf  n  f  gf  P  O.R.  PF 
B5  15  0.0394  0.0199  0.0239  0.0120  NS  0.63   
B7  35  0.0887  0.0454  23  0.0612  0.0311  NS  0.67   
B8  18  0.0443  0.0224  22  0.0612  0.0311  NS  1.36   
B12  24  0.0616  0.0313  0.0106  0.0053  0.0001  0.16  0.43 
B13  0.0197  0.0099  0.0106  0.0053  NS  0.53   
B14  25  0.0616  0.0313  17  0.0452  0.0229  NS  0.71   
B15  12  0.0296  0.0149  10  0.0266  0.0134  NS  0.89   
B16  0.0123  0.0062  0.0080  0.0040  NS  0.64   
B17  14  0.0394  0.0199  0.0053  0.0027  0.0039  0.15  0.41 
B18  13  0.0320  0.0161  18  0.0505  0.0256  NS  1.55   
B21  0.0172  0.0087  0.0160  0.0080  NS  0.92   
B22  0.0099  0.0049  0.0000  0.0000  NS  0.12   
B27  10  0.0246  0.0124  14  0.0372  0.0188  NS  1.55   
B35  63  0.1576  0.0822  45  0.1197  0.0617  NS  0.70   
B37  0.0172  0.0087  15  0.0399  0.0201  NS  2.43   
B38  0.0222  0.0111  19  0.0505  0.0256  0.0322  2.42   
B39  0.0148  0.0074  0.0133  0.0067  NS  0.90   
B40  11  0.0296  0.0149  0.0053  0.0027  0.0215  0.19  0.40 
B41  0.0246  0.0124  0.0133  0.0067  NS  0.59   
B42  0.0148  0.0074  0.0080  0.0040  NS  0.53   
B44  33  0.0837  0.0428  42  0.1170  0.0603  NS  1.48   
B45  0.0099  0.0049  0.0106  0.0053  NS  1.08   
B46  0.0025  0.0012  0.0000  0.0000  NS  0.36   
B48  0.0172  0.0087  0.0000  0.0000  0.0307  0.08  0.00 
B49  0.0049  0.0025  0.0186  0.0094  NS  3.89   
B50  0.0025  0.0012  0.0027  0.0013  NS  1.08   
B51  12  0.0296  0.0149  26  0.0691  0.0352  0.01  2.55   
B52  0.0049  0.0049  0.0186  0.0094  NS  1.92   
B53  0.0246  0.0124  20  0.0532  0.0270  0.0211  2.57   
B54  0.0074  0.0037  0.0027  0.0013  NS  0.36   
B55  0.0025  0.0012  0.0080  0.0040  NS  3.28   
B56  0.0074  0.0037  0.0000  0.0000  NS  0.21   
B57  0.0172  0.0087  0.0213  0.0107  NS  1.23   
B58  0.0025  0.0012  0.0080  0.0040  NS  3.28   
B60  0.0148  0.0074  12  0.0319  0.0161  NS  2.70   
B61  0.0074  0.0037  0.0186  0.0094  NS  2.58   
B62  0.0074  0.0037  10  0.0266  0.0134  0.0465  3.75   
B63  0.0074  0.0037  0.0080  0.0040  NS  1.08   
B64  0.0025  0.0012  0.0000  0.0000  NS  0.36   
B65  0.0074  0.0037  0.0000  0.0000  NS  0.15   
B67  0.0000  0.0000  0.0053  0.0027  NS  5.46   
B75  0.0025  0.0012  0.0000  0.0000  NS  0.36   
Black  0.0049  0.0025  0.0106  0.0053  NS  2.18   

n: number of antigen, f: antigen frequencies, gf: gene frequencies, P: probability, NS: no significant, O.R.: Odds ratio, N: number of individuals, ESRD: end stage renal disease, PF: preventive fraction.

Table 3.

HLA-A9 and HLA-B12 negative association with ESRD remained after Bonferroni correction applied.

Antígeno HLA  Casos (a+)  Casos (b−)  Control (c+)  Control (d−)  OR 95% IC  P  Pc 
A9  370  24  382  0.25 (0.1043–0.6385)  0.001187  0.0308 
B12  372  24  382  0.17 (0.0588–0.4979)  0.000153  0.0065 
B17  374  14  392  0.14 (0.0338–0.6632)  0.0030  0.129 
B38  19  357  397  2.34 (1.0487–5.2553)  0.025  1.075 
B40  374  11  395  0.19 (0.0422–0.8720)  0.015  0.645 
B48  376  400  0.08 (0.0045–1.4572)  0.019  0.817 
B51  26  350  12  394  2.43 (1.2124–4.9065)  0.0077  0.3311 
B53  20  356  397  2.47 (1.1139–5.5127)  0.017  0.731 
B62  10  366  403  3.67 (1.0024–13.4387)  0.033  1.419 

O.R.: Odds ratio, P: probability, Pc: P Bonferroni corrected.

The haplotypes positively associated with ESRD were: A2-B51, A2-B53, A23-B38 and A68-B38. The A2-B48, A2-B12, A9-B35 and A28-B40 haplotypes were negatively associated with ESRD, expressing relative risks lower to 1 (Table 4).

Table 4.

Association of HLA-A-B two loci haplotypes class I in patients with ESRD and control group of the Mestizos Zulian population.

HLA  Controls N=203ESRD patients N=188   
Haplotype  Hf  Δ Delta  P  Hf  Δ Delta  P  O.R.  P 
A2-B51  0.00002237  −0.002415  NS  0.0101161622  0.004846  NS  4.41  0.0018 
A2-B53  −0.00171029  −0.003739  0.0031  0.005877061  0.001800  NS  29.66  <0.0001 
A23-B38  −0.00018449  −0.000322  NS  0.002884577  0.002229  0.0292  11.96  0.0255 
A68-B38  −0.00005598  −0.000097  NS  0.003025816  0.002821  0.0013  11.96  0.0255 
A2-B48  0.00375225  0.002329  0.0338  0.000000000  0.000000  NS  0.08  0.0316 
A2-B12  0.01262618  0.002548  NS  −0.000098220  −0.000899  NS  0.06  0.0002 
A9-B35  0.00661940  0.004466  0.0131  −0.000308540  −0.000802  NS  0.15  0.004 
A28-B40  0.00408248  0.003616  0.0002  0.000000010  −0.000065  NS  0.07  0.0159 

N: number of individuals, Hf: haplotype frequency, P: probability (exact Fischer or Yates corrected testing), O.R.: Odds ratio, ESRD: end-stage renal disease, Δ Delta: linkage disequilibrium.

Discussion

The range of age of the majority of patients with ESRD of Zulia state was located between 20 and 44 years of age (the median age is 34.3 years), belonging to the most productive labor force segment of the population. The US RENAL DATA SYSTEM (USRDS) has reported that the majority of patients with ESRD have a range of age between 45 and 64 years. The median age of the prevalent ESRD population in USA has increased 3.2 percent since 2000, reaching 59.4 in 2008.19 This age difference between our patients and those reported in USA could be because in our patients, the proliferative glomerulonephritis was the main cause of ESRD, this glomerular injury may be secondary to endemic infections including streptococcal infection, schistosomiasis, etc., frequent infections to younger ages and which have low frequency in developed countries, where it was indicated as the main cause of diabetes and hypertension, diseases characteristic of older age. In Zulia population, the men with ESRD are 1.65 times the number of women, not reflecting significant differences.

HLA-B38, B51, B53 and B62 antigens were positively associated in patients with ESRD in Zulia population while the HLA-A9, B12, B17, B40 and B48 antigens were shown as protective antigens. The HLA-B53 antigen has been reported previously, associated with an increased risk for alloantibodies sensitization and with decreased graft survival in patients with ESRD (PRA response, Panel Reactive Antibodies), while, the HLA-B12 and B40, associated negatively in this study, have been reported associated with a significantly decreased risk for sensitization in these patients.4 However, the presence of anti-HLA alloantibodies was not evaluated in this study.

Since the early 1980s, the USRDS has reported racial and ethnic discrepancies in ESRD. The rates in the African American and Native American populations were 3.6 and 1.8 times greater, respectively, than the rate among whites.19 Perhaps this is due, at least in part, to hypertensive nephrosclerosis, nephropathy secondary to diabetes mellitus types I and II, and chronic glomerulonephritis, occur more frequently in African Americans. In this population, the existence of a first-degree relative with ESRD raises nine times the risk of developing this condition.20 It should be noted that the Venezuelan population is a mixture of native Indigenous with Caucasian immigrants from different regions of Europe and Africans blacks.21 Of positively associated antigens in this study, only HLA-B53 was present in previous studies in healthy Zulian population with a frequency of 2.1%.22 In the town of Curiepe, Miranda state, inhabited mainly by people of Negroid origin, this antigen reported a frequency of 7%,23 meanwhile, was not present in indigenous Wayuu.22 The Black Colombians show equally HLA-B53 high frequency (11.3%),22 and also, in the Cuban population, the HLA-B*5301 allele (10.7%).24 In another research in our laboratory, in the Zulia population, the HLA-B*5301 allele was the unique subtype found (1.82%).25 Apparently, the black and mixed populations with a high compound of the HLA-B53 are most affected regarding the presence HLA genes associated to ESRD, which coincide with high prevalence feature of the disease.

Previous studies identified several HLA supermotifs (HLA-A and B supertype), each of which corresponds to the ability of peptide ligands to bind several different HLA alleles.26,27 HLA-B51, positively associated with ESRD in this study and B*5301, reported in our healthy population, belong to B7-supertype. Equally, B44, negatively associated with ESRD, and B4001, also reported in our healthy population, belong to the B44-supertype. Furthermore B62 and A9 antigens are included in the B62-supertype and A24-supertype, respectively. Nevertheless, definition of HLA-supertypes requires DNA-based typing because some HLA specificities are difficult to type by serological methods. Notwithstanding, it will be possible to identify some peptides associated to progression or protection to ESRD based on HLA-supertyping molecular definition.

Many studies have described association between HLA and a variety of kidney diseases and with ESRD due to a certain disease, but are few studies evaluating the association with progression to ESRD. This HLA association with progression has been studied in other diseases such as diabetes and chronic lymphocytic leukemia.28-30 In the case of the association with progression to ESRD, these studies have shown an increased HLA-A78 and decreased HLA-B14 in Brazilian patients.31 Others have reported increased HLA-A33, -A11 and -B49.32 These findings provide support to the idea that HLA polymorphism may influence susceptibility to renal disease progression. Both studies were carried out without regard to primary renal disease leading to ESRD. Karahan et al. studied the association of HLA with the primary diseases leading to ESRD in Turkish patients reporting a negative association between almost all A locus antigens and chronic glomerulonephritis and hypertensive nephrosclerosis, meanwhile, found a positive association between the HLA-B58 and HLA-DRB1*03 with amyloidosis and diabetic nephropathy, respectively.33 Studies such as these suggest that the determination of HLA may be useful in preventing both the progression to ESRD as the primary disease recurrence post-transplantation.

Finally, the differences in the results published by different authors may be due to the large variability in the frequency of HLA alleles present in different populations or ethnic groups. Other explanation may be linkage disequilibrium between these alleles HLA and other nearby genes involved in regulating the immune response. For example, it has been reported that polymorphism in genes encoding certain cytokines, including IL-6, IL-4 and TNF may be involved in the progression to ESRD.34

This study confirms the existence, in our population, of HLA Class I antigens and/or haplotypes directly associated, with the progression or protection of the ESRD. Finally this could orientate the physician to get a prognosis and treatment. Furthermore, molecular studies will allow for the classification of types, subtypes and/or supertypes of those alleles involved in progression to ESRD.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgment

We are grateful to Zulay Layrisse for critical review of the manuscript.

References
[1]
J.C. Fink.
Current outcomes for dialysis patients and improving quality of care for dialysis patients.
Principles and practice of dialysis, 4th edition, pp. 752
[2]
W.G. Walter, J.D. Neaton, J.A. Cutler.
Renal function change in hypertensive members of the multiple risk factor intervention trial: racial and treatment effects.
JAMA, 268 (1992), pp. 3085-3091
[3]
F. Locatelli, L. Del Vecchio.
National history and factors affecting the progression of chronic renal failure.
Mechanisms and management of progressive renal failure, pp. 20-79
[4]
E. Heisse, C. Manning, L. Tracker.
HLA phenotypes of ESRD patients are risk factors in the panel-reactive antibody (PRA) response.
Clin Transplant, 15 (2001), pp. 22-27
[5]
S. Barocci, S. Fiordoro, G. Santori, U. Valente, M. Mossa, P. Antonelli, et al.
Alport syndrome: HLA association and kidney graff outcome.
Eur J Inmunogenet, 31 (2004), pp. 115-119
[6]
I.I. Doxiadis, P. De Lange, E. De Vries, G.G. Persijn, F.H. Claas.
Protective and susceptible HLA polymorphisms in IgA nephropathy patients with end-stage renal failure.
Tissue Antigens, 57 (2001), pp. 344-347
[7]
H. Dunckley, J.R. Chapman, J. Burke, J. Charlesworth, J. Hayes, E. Haywood, et al.
HLA-DR and DQ genotyping in anti-GBM disease.
Dis Markers, 9 (1991), pp. 249-256
[8]
M. Fisher, C.D. Pusey, R.W. Vauhan, A.J. Rees.
Susceptibility to Goodpasture¿s disease is strongly associated with HLA-DRB1 genes.
Kidney Int, 51 (1997), pp. 222-229
[9]
M.R. Garavoy.
Immunogenetic associations in nephritic states.
Contemp Issues Nephrol, 9 (1982), pp. 259-282
[10]
D.J. Goodman, B. Clarke, R.N. Hope, P.J. Miach, J.K. Dawborn.
Familial focal glomerulosclerosis: a genetic linkage to the HLA locus?.
Am J Nephrol, 15 (1995), pp. 442-445
[11]
B. Huey, K. McCormick, J. Capper, C. Ratliff, B.W. Colombe, M.R. Garavoy, et al.
Associations of HLA-DR and HLA-DQ types with anti-GBM nephritis by sequence-specific oligonucleotide probe hybridization.
Kidney Int, 44 (1993), pp. 307-312
[12]
B. Mercier, B. Bourbigot, O. Raguenes, E. Rondeau, P. Simon, C. Legendre, et al.
HLA class II typing of Goodpasture¿s syndrome affected patients.
J Am Soc Nephrol, 3 (1992), pp. 658
[13]
Z. Layrisse, B. Rodriguez Iturbe, R. Garcia Ramirez, A. Rodriguez, J. Tiwari.
Family studies of the HLA system in acute post-streptococcal glomerulonephritis.
Hum Immunol, 7 (1983), pp. 177-185
[14]
H. Festenstein, P. Démant.
Sistema Principal de Histocompatibilidad MHS en el humano: HLA.
Inmunogenética fundamental, biología y aplicaciones clínicas de HLA y H-2, pp. 298
[15]
Mattiuz Pl, D. Ihde, A. Piazza, R. Cepellini, W.F. Bodmer.
New approaches to the population genetic segregation analysis of the HLA system.
Histocompatibility testing 1970, pp. 193-205
[16]
C. Gorodezky.
Métodos para el análisis estadístico del complejo HLA.
Mexico, (2000),
[17]
J.B.S. Haldane.
The estimation and significance of the logarithm of a ratio of frequencies.
Ann Hum Genet, 20 (1955), pp. 309-311
[18]
B. Woolf.
On estimating the relation between blood group and disease.
Ann Hum Genet, 19 (1955), pp. 251-253
[19]
U.S. RENAL DATA SYSTEM: USRDS 2010. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Chapter 2: Incidence and Prevalence National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2010.
[20]
B.I. Freedman, B.J. Spray, A.B. Tuttle, V.M Buckalew Jr..
The familial risk of end-stage renal disease in African-Americans.
Am J Kidney Dis, 21 (1993), pp. 387-393
[21]
A.A. Zachary, W.B. Bias, A. Johnson, S.M. Rose, M.S. Leffell.
Antigen, allele and haplotype frequencies report of the ASHI minority antigens workshops: part 1, African-Americans.
Hum Immunol, 62 (2001), pp. 1127-1136
[22]
S. Rivera, J. Weir, M. Echeverria, G. Márquez, A. Fuenmayor, M. Hassanhi, et al.
HLA en la Población Zuliana de Venezuela.
Inmunología, 17 (1998), pp. 137-145
[23]
M.C. Bortolini, T.A. Weimer, M.H.L.P. Franco, F.M. Salzano, Z. Layrisse, H. Sheneider, et al.
Genetic studies in three South American Black populations.
Gene Geogr, 6 (1992), pp. 1-16
[24]
F. Williams, A. Meenagh, C. Darke, A. Acosta, A. Daar, C. Gorodezky, et al.
Analysis of the distribution of HLA-B alleles in population from five continents.
Hum Immunol, 62 (2001), pp. 645-650
[25]
S. Rivera, R. Hernandez, M. Hassanhi, M. Montiel, G. Márquez, C. Villalobos, et al.
Molecular characterization of the mayor histocompatibility complex class I by PCR-SSOP in Zulian population: Venezuela.
Ciencia, 12 (2004), pp. 132-147
[26]
A. Sette, J. Sidney.
HLA supertypes and supermotifs: a functional perspective on HLA polymorphism.
Curr Opin Immunol, 10 (1998), pp. 478-482
[27]
A. Sette, J. Sidney.
Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism.
Immunogenetics, 50 (1999), pp. 201-212
[28]
M. Hojjat-Farsangi, M. Jeddi-Tehrani, A.A. Amirzargar, S.M. Razavi, R.A. Sharifian, H. Rabbani, et al.
Human Leukocyte Antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia.
Hum Immunol, 69 (2008), pp. 666-674
[29]
B.D. Thait, P.G. Colman, G. Morahan, L. Marchinovska, E. Dore, S. Geller, et al.
HLA genes associated with autoimmunity and progression to disease in type I diabetes.
Tissue Antigens, 61 (2003), pp. 146-153
[30]
T.Y. Wong, K.J. Cruickshank, R. Klein, B.E. Klein, S.E. Moss, M. Palta, et al.
HLA-DR3 y DR4 and their relation to the incidence and progression of diabetic retinopathy.
Ophtalmology, 109 (2002), pp. 275-281
[31]
J.C. Crispim, C.T. Méndes-Júnior, I.J. Wastowski, G. Martelli, L.T. Saber, D.M. Rassi, et al.
HLA polymorphism as incidence factor in the progression to ESRD in Brazilian patients awaiting kidney transplant.
Transplant Proc, 40 (2008), pp. 1333-1336
[32]
P.P. Davod, N. Farhadi, M. Najafizadeh.
Protective and Susceptible HLA Class I Genes in Patients with End-Stage Renal Disease.
Res J Biol Sc, 3 (2008), pp. 1344-1346
[33]
G. Karahan, Y. Seyhun, F. Oqus, C. KeK, A. Orial, H. Yacizi, et al.
Impact of HLA on the underlying primary diseases in Turkish patients with end-stage renal disease.
Renal Failure, 31 (2009), pp. 44-49
[34]
P. Ranganath, G. Tripathi, R.K. Sharma, S.N. Sankhwr, S. Agrawal.
Rol of non-HLA genetic variants in End Stage Renal Disease.
Tissue Antigens, 74 (2009), pp. 147-155
Copyright © 2011. Sociedad Española de Inmunología
Descargar PDF
Opciones de artículo